Trials / No Longer Available

No Longer AvailableNCT05683470

Expanded Access RBS2418 Treatment

Expanded Access to RBS2418 for an Individual Patient With Pancreatic Cancer

Status: No Longer Available
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Riboscience, LLC. · Industry
Sex: Female
Age: —
Healthy volunteers: —

Summary

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

Detailed description

Given lack of any therapeutic options such as standard of care chemotherapy for this single patient owing to lack of tolerability and opportunity to enroll in any clinical trial due to extent of disease, patient desires to try compassionate use protocol with RBS2418, an oral immunotherapeutic agent that is currently in clinical trials and is well tolerated by patients. Furthermore, patient's tumor has been shown to express ENPP1, the protein targeted by RBS2418

Conditions

Expanded Access in Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	RBS2418	RBS2418 will be administered orally at 200 mg two times per day (BID).

Timeline

First posted: 2023-01-13
Last updated: 2024-02-21

Source: ClinicalTrials.gov record NCT05683470. Inclusion in this directory is not an endorsement.